Who are Daclatasvir and Asunaprevir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SOF+RBV, PTV/r/OBV/DSV, EXVIERA, Sofosbuvir/Velpatasvir + Ribavirin, sofosbubir/velpatasvir/voxilaprevir, Combined therapy LDV and SOF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daclatasvir-and-asunaprevir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Daclatasvir and Asunaprevir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daclatasvir and Asunaprevir (Daclatasvir and Asunaprevir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral. Area: Infectious Disease.

phase 2 Direct-acting antiviral HCV NS5A, HCV NS3/4A protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Daclatasvir and Asunaprevir (Daclatasvir and Asunaprevir) — Sang Gyune Kim. Daclatasvir and Asunaprevir are direct-acting antivirals that inhibit the HCV NS5A and NS3/4A proteases, respectively.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Daclatasvir and Asunaprevir TARGET	Daclatasvir and Asunaprevir	Sang Gyune Kim	phase 2	Direct-acting antiviral	HCV NS5A, HCV NS3/4A protease
SOF+RBV	SOF+RBV	Humanity and Health Research Centre	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B RNA polymerase; viral replication machinery
PTV/r/OBV/DSV	PTV/r/OBV/DSV	National Taiwan University Hospital	marketed	HCV direct-acting antiviral combination	HCV NS3/4A protease, NS5A, NS5B polymerase
EXVIERA	EXVIERA	HaEmek Medical Center, Israel	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS5B, NS3/4A protease
Sofosbuvir/Velpatasvir + Ribavirin	Sofosbuvir/Velpatasvir + Ribavirin	Peking University People's Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, HCV NS5A protein
sofosbubir/velpatasvir/voxilaprevir	sofosbubir/velpatasvir/voxilaprevir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, NS5A protein, NS3/4A protease
Combined therapy LDV and SOF	Combined therapy LDV and SOF	Yassin Abdelghaffar Charity Center for Liver Disease and Research	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral class)

Hospices Civils de Lyon · 1 drug in this class
Iran Hepatitis Network · 1 drug in this class
Qing XIe · 1 drug in this class
Sang Gyune Kim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daclatasvir and Asunaprevir — Competitive Intelligence Brief. https://druglandscape.com/ci/daclatasvir-and-asunaprevir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab